1. Home
  2. BAFN vs IGC Comparison

BAFN vs IGC Comparison

Compare BAFN & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BayFirst Financial Corp.

BAFN

BayFirst Financial Corp.

N/A

Current Price

$5.78

Market Cap

26.6M

Sector

Finance

ML Signal

N/A

Logo IGC Pharma Inc.

IGC

IGC Pharma Inc.

HOLD

Current Price

$0.27

Market Cap

28.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BAFN
IGC
Founded
1999
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.6M
28.4M
IPO Year
2021
2005

Fundamental Metrics

Financial Performance
Metric
BAFN
IGC
Price
$5.78
$0.27
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.25
AVG Volume (30 Days)
17.9K
482.1K
Earning Date
04-30-2026
03-19-2026
Dividend Yield
1.00%
N/A
EPS Growth
N/A
59.09
EPS
N/A
N/A
Revenue
N/A
$1,271,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$13.06
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.26
$0.24
52 Week High
$15.28
$0.50

Technical Indicators

Market Signals
Indicator
BAFN
IGC
Relative Strength Index (RSI) 55.97 46.06
Support Level $4.80 $0.25
Resistance Level $5.90 $0.31
Average True Range (ATR) 0.35 0.01
MACD 0.09 -0.00
Stochastic Oscillator 81.82 32.89

Price Performance

Historical Comparison
BAFN
IGC

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.

About IGC IGC Pharma Inc.

IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.

Share on Social Networks: